12:45 PM - 1:00 PM: Lunch and Registration
1:00 PM - 1:05 PM: Welcome and Introduction
1:05 PM - 1:20 PM: Current Practice: Checkpoint Inhibitors in Unresectable Stage III NSCLC – Edward B. Garon, MD, MS
1:20 PM - 1:45 PM: Open Questions: Case Discussions on Optimal Integration of Checkpoint Inhibitors into the Management of Unresectable Stage III NSCLC – Julie Brahmer, MD, MSc
1:45 PM - 1:55 PM: Future Directions: Moving Checkpoint Inhibitors into Earlier NSCLC Settings – Naiyer Rizvi, MD
1:55 PM - 2:00 PM: Final Panel Discussion and Audience Question and Answer Session
Date / Time
Walter E. Washington Convention Center
Julie Brahmer, MD
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Edward Garon, MD
Associate Clinical Professor
Director, Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California
Naiyer Rizvi, MD
Price Family Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy
Columbia University Medical Center
New York, New York
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to integrate immune checkpoint inhibitors into treatment of their patients with stage III non-small-cell lung cancer.
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.
- Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
- Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
- Identify subsets of patients with stage III NSCLC in which current research is conclusive, suggestive, or not available for benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
- Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.